Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in Familial Chylomicronemia Syndrome
NCT05130450Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Feb 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 11
01
Overview
A Phase 3 trial of olezarsen in familial chylomicronemia syndrome (FCS), sponsored by Ionis Pharmaceuticals. Started Nov 2021; status: active, not recruiting.
02
Drugs
olezarsen
03
Conditions
familial chylomicronemia syndrome (FCS)
Beyond the preview
Go deeper on NCT05130450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130450.